At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the Central Nervous System (CNS). We combine the efforts of medicinal chemists, pharmacologists, biologists and clinical development scientists into a vibrant team that translates world-class research expertise into novel drugs. The company's lead product, ITI-007 is a novel first-in-class 5-HT2A antagonist, Dopamine receptor phosphoprotein modulator (DPPM) designed to treat multiple deficits in patients with schizophrenia while lacking the side-effects of existing antipsychotic drugs. ITI has also developed a state of the art technology platform, called CNSProfile™ that is capable of generating a unique molecular signature for drug compounds. This profile provides us with a proprietary window into the intracellular action of CNS drugs or drug candidates. We use this tool to fingerprint the intracellular molecular actions of existing drugs and to drive our internal drug discovery and development. Our technology has also enabled the company to examine the toxic effects of brain damaging nerve agents, and as a result, we are involved in collaborative efforts with several military and contract organizations to develop antidotes to chemical warfare agents. Based upon our understanding of the Central Nervous System we have discovered novel drug candidates with promise for treating the panoply of symptoms associated with the transition from peri-menopausal to post-menopausal states. Intra-Cellular Therapies was founded in 2002 by Drs. Paul Greengard, Sharon Mates and Allen Fienberg. The company is headquartered in New York City.

Sumitomo Seika Chemicals Co., Ltd. engages in the manufacture and sale of chemical products. It operates through the following segments: Chemicals, Super Absorbent Polymers, and Gases and Engineering. The Chemicals segment provides industrial chemicals, pharmaceutical products, polymers, and functional products. The Super Absorbent Polymers offers absorbent polymers used in disposable diapers, sanitary napkins, and industrial materials. The Gases and Engineering segment deals with medical gas, chemical gas, electronics gas, gas generators, and general chemical engineering equipment. The company was founded on July 20, 1944 and is headquartered in Osaka, Japan.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Sanovel Ila�� Sanayi ve Ticaret AS engages in the manufacture of pharmaceutical products. It develops medicaments, such as antihistamines, expectorants, decongestants, antibiotics, and anti-inflammatory drugs, as well as offers research and development services. The company was founded by Erol Toks��z in 1983 and is headquartered in Istanbul, Turkey.

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Dow Global Technologies LLC manufactures chemicals such as polymers.

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and smoking cessation.

Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.

InCube Labs is a life sciences research lab focused on developing medical breakthroughs that dramatically improve patient outcomes. Their multi-disciplinary approach integrates traditional device technologies such as electronics, software, mechanical engineering and material science, with innovations from the pharmaceutical industry, often involving protein chemistry, pharmacology and cell biology. InCube is led by Mir Imran, an accomplished medical innovator, entrepreneur and venture capitalist, who has founded more than 20 life sciences companies and holds more than 200 patents. Many of Imran’s innovations have resulted in new standards of care, including the first FDA-approved Automatic Implantable Cardioverter Defibrillator.

Capsugel Belgium NV provides dosage forms and solutions. The firm also sells equipment for filling empty and liquid capsules and equipment for sealing liquid capsules. The company was founded on October 1, 1961 and is headquartered in Bornem, Belgium.

Cambridge Consultants Ltd. develops breakthrough products. The firm specializes in innovation management, human factors and industrial design, mechanical engineering, signal processing and algorithms, sensing technologies, physical sciences, and synthetic biology. The company was founded in 1960 and is headquartered in Cambridge, the United Kingdom.

Medix, Inc., part of Owens & Minor, Inc., is an American company located in Waunakee, WI. The firm distributes medical and surgical supplies. It was acquired by Owens & Minor, Inc. on July 30, 1999.

Boehringer Ingelheim KG, part of C.H. Boehringer Sohn AG & Co. KG, is a company headquartered in Biberach, Germany. The firm wholesales pharmaceutical products. It was founded in 1981.

Bespack Co., Ltd. engages in the manufacture and sale of plastic packaging containers and medical-related products. It also provides the sale of various sheets and processed products of synthetic resins, films, and packaging machines. The company was founded on October 24, 1966 and is headquartered in Tokyo, Japan.

IKA-Werke GmbH & Co. KG is a German private company headquartered in Staufen with a presence in several countries. The firm manufactures and wholesales laboratory instrument & equipment. It was founded in 1910. Werner Kanzinger, Erhard Eble and René Stiegelmann are the current co-CEOs of the company.